tiprankstipranks
Trending News
More News >

Kymera Therapeutics price target raised to $60 from $52 at Citi

Citi raised the firm’s price target on Kymera Therapeutics (KYMR) to $60 from $52 and keeps a Buy rating on the shares. Positive Phase 1 healthy volunteer data for KT-621 de-risks the asset and underscores the potential of Kymera’s platform, the analyst tells investors. The firm believes this potent efficacy, clean safety, and promising biomarker data, though in healthy volunteers, “strongly derisks” KT-621 and Citi increased its view of the odds of success for KT-621 to 15% from 10% and now models peak 2030 sales of $520M, the analyst added.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue